{"table": "Stat_Reg", "nct_id": "NCT00387465", "missing_fields": ["Central_Random", "Rand_Ratio", "No_Stratification", "IRC", "Subgroup", "Adaptive_Design", "Interim", "Timing_IA"], "response": "```json\n{\n  \"Central_Random\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Rand_Ratio\": {\"value\": \"\", \"evidence\": \"\"},\n  \"No_Stratification\": {\"value\": \"\", \"evidence\": \"\"},\n  \"IRC\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Subgroup\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Adaptive_Design\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Interim\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Timing_IA\": {\"value\": \"\", \"evidence\": \"\"}\n}\n```", "parsed": {"Central_Random": {"value": "", "evidence": ""}, "Rand_Ratio": {"value": "", "evidence": ""}, "No_Stratification": {"value": "", "evidence": ""}, "IRC": {"value": "", "evidence": ""}, "Subgroup": {"value": "", "evidence": ""}, "Adaptive_Design": {"value": "", "evidence": ""}, "Interim": {"value": "", "evidence": ""}, "Timing_IA": {"value": "", "evidence": ""}}, "normalized": {"Central_Random": {"value": "", "evidence": ""}, "Rand_Ratio": {"value": "", "evidence": ""}, "No_Stratification": {"value": "", "evidence": ""}, "IRC": {"value": "", "evidence": ""}, "Subgroup": {"value": "", "evidence": ""}, "Adaptive_Design": {"value": "", "evidence": ""}, "Interim": {"value": "", "evidence": ""}, "Timing_IA": {"value": "", "evidence": ""}}, "batch_index": 1, "batch_total": 4}
{"table": "Stat_Reg", "nct_id": "NCT00387465", "missing_fields": ["Alpha", "Sided", "Power", "Alpha_Spend_Func", "Gatekeeping_Strategy", "Consistency_Sens_Ana_PE", "Consistency_Sens_Ana_SE", "Post_Hoc_Ana"], "response": "```json\n{\n  \"Alpha\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Sided\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Power\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Alpha_Spend_Func\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Gatekeeping_Strategy\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Consistency_Sens_Ana_PE\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Consistency_Sens_Ana_SE\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Post_Hoc_Ana\": {\"value\": \"\", \"evidence\": \"\"}\n}\n```", "parsed": {"Alpha": {"value": "", "evidence": ""}, "Sided": {"value": "", "evidence": ""}, "Power": {"value": "", "evidence": ""}, "Alpha_Spend_Func": {"value": "", "evidence": ""}, "Gatekeeping_Strategy": {"value": "", "evidence": ""}, "Consistency_Sens_Ana_PE": {"value": "", "evidence": ""}, "Consistency_Sens_Ana_SE": {"value": "", "evidence": ""}, "Post_Hoc_Ana": {"value": "", "evidence": ""}}, "normalized": {"Alpha": {"value": "", "evidence": ""}, "Sided": {"value": "", "evidence": ""}, "Power": {"value": "", "evidence": ""}, "Alpha_Spend_Func": {"value": "", "evidence": ""}, "Gatekeeping_Strategy": {"value": "", "evidence": ""}, "Consistency_Sens_Ana_PE": {"value": "", "evidence": ""}, "Consistency_Sens_Ana_SE": {"value": "", "evidence": ""}, "Post_Hoc_Ana": {"value": "", "evidence": ""}}, "batch_index": 2, "batch_total": 4}
{"table": "Stat_Reg", "nct_id": "NCT00387465", "missing_fields": ["Intercurrent_Events", "Success_Criteria_Text", "Reg_Alignment", "Reg_Audit", "Consistency_MRCT", "Fast_Track", "Breakthrough", "Priority_Review"], "response": "```json\n{\n  \"Intercurrent_Events\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Success_Criteria_Text\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Reg_Alignment\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Reg_Audit\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Consistency_MRCT\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Fast_Track\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Breakthrough\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Priority_Review\": {\"value\": \"\", \"evidence\": \"\"}\n}\n```", "parsed": {"Intercurrent_Events": {"value": "", "evidence": ""}, "Success_Criteria_Text": {"value": "", "evidence": ""}, "Reg_Alignment": {"value": "", "evidence": ""}, "Reg_Audit": {"value": "", "evidence": ""}, "Consistency_MRCT": {"value": "", "evidence": ""}, "Fast_Track": {"value": "", "evidence": ""}, "Breakthrough": {"value": "", "evidence": ""}, "Priority_Review": {"value": "", "evidence": ""}}, "normalized": {"Intercurrent_Events": {"value": "", "evidence": ""}, "Success_Criteria_Text": {"value": "", "evidence": ""}, "Reg_Alignment": {"value": "", "evidence": ""}, "Reg_Audit": {"value": "", "evidence": ""}, "Consistency_MRCT": {"value": "", "evidence": ""}, "Fast_Track": {"value": "", "evidence": ""}, "Breakthrough": {"value": "", "evidence": ""}, "Priority_Review": {"value": "", "evidence": ""}}, "batch_index": 3, "batch_total": 4}
{"table": "Stat_Reg", "nct_id": "NCT00387465", "missing_fields": ["Accelerated_App", "Orphan_Drug", "Pediatric", "Rare_Disease", "Obj_Primary", "Primary_EP_SC", "Key_Second_EP_SC"], "response": "```json\n{\n  \"Accelerated_App\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Orphan_Drug\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Pediatric\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Rare_Disease\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Obj_Primary\": {\"value\": \"\", \"evidence\": \"\"},\n  \"Primary_EP_SC\": {\"value\": \"S\", \"evidence\": \"Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT) | Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy\"},\n  \"Key_Second_EP_SC\": {\"value\": \"S\", \"evidence\": \"Effect of Entinostat and Azacitidine on DNA Methylation and Response\"}\n}\n```", "parsed": {"Accelerated_App": {"value": "", "evidence": ""}, "Orphan_Drug": {"value": "", "evidence": ""}, "Pediatric": {"value": "", "evidence": ""}, "Rare_Disease": {"value": "", "evidence": ""}, "Obj_Primary": {"value": "", "evidence": ""}, "Primary_EP_SC": {"value": "S", "evidence": "Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT) | Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy"}, "Key_Second_EP_SC": {"value": "S", "evidence": "Effect of Entinostat and Azacitidine on DNA Methylation and Response"}}, "normalized": {"Accelerated_App": {"value": "", "evidence": ""}, "Orphan_Drug": {"value": "", "evidence": ""}, "Pediatric": {"value": "", "evidence": ""}, "Rare_Disease": {"value": "", "evidence": ""}, "Obj_Primary": {"value": "", "evidence": ""}, "Primary_EP_SC": {"value": "", "evidence": ""}, "Key_Second_EP_SC": {"value": "", "evidence": ""}}, "batch_index": 4, "batch_total": 4}
